Leading the Long Noncoding RNA Pack: PELATON in Human Atherosclerosis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Non-invasive assessment techniques for renal fibrosis: advances and perspectives.Renal failure · 2025
   Review
2. Non-Coding RNA Involved in the Pathogenesis of Atherosclerosis-A Narrative Review.Diagnostics (Basel, Switzerland) · 2024
   Review
3. High expression of lncRNA PELATON serves as a risk factor for the incidence and prognosis of acute coronary syndrome.Scientific reports · 2022
   Article
4. Clinical Parameters and Epigenetic Biomarkers of Plaque Vulnerability in Patients with Carotid Stenosis.International journal of molecular sciences · 2022
   Review
5. NcRNAs in Vascular and Valvular Intercellular Communication.Frontiers in molecular biosciences · 2021
   Review

Corrections and comments

• Comment on
  Novel Plaque Enriched Long Noncoding RNA in Atherosclerotic Macrophage Regulation (PELATON).2020

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as